Clinical significance of smoking cessation in subjects with cancer: A 30-year review

Respiratory Care

Volumn 59, Issue 12, 2014, Pages 1924-1936

  Florou, Angeliki N ^a   Gkiozos, Ioannis C H ^b   Tsagouli, Sophia K ^b   Souliotis, Kyriakos N ^c   Syrigos, Konstantinos N ^b  

^a Evgenidion Hospital   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF PELOPONNESE   (Greece)

Author keywords

Lung cancer; Quality of life; Smoking; Smoking cessation

Indexed keywords

ERLOTINIB; NICOTINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISEASE COURSE; HUMAN; LUNG CANCER; MEDICAL LITERATURE; MORTALITY; MOUTH CANCER; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; SMALL CELL LUNG CANCER; SMOKING CESSATION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THERAPY RESISTANCE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; HEALTH STATUS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; SMOKING; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; HEALTH STATUS; HUMANS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; SMOKING CESSATION; SURVIVAL RATE;

EID: 84924708581     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02559     Document Type: Article

References (44)

1. Oppeltz RF, Jatoi I. Tobacco and the escalating global cancer burden. J Oncol 2011;2011:408104.
2. Zon RT, Goss E, Vogel VG, Chlebowski RT, Jatoi I, Robson ME, et al. American Society of Clinical Oncology Policy Statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol 2009;27(6):986-993.
3. Gritz ER, Fingeret MC, Vidrine DJ, Lazev AB, Mehta NV, Reece GP. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 2006;106(1):17-27.
4. Nayan SN, Gupta MK, Sommer DD. Evaluating smoking cessation interventions and cessation rates in cancer patients: a systematic review and meta-analysis. ISRN Oncol 2011;2011:849023.
5. Wieseler B, McGauran N. Reporting a systematic review. Chest 2010;137(5):1240-1246.
6. Johnston-Early A, Cohen MH, Minna JD, Paxton LM, Fossieck BE Jr, Ihde DC, et al. Smoking abstinence and small cell lung cancer survival: an association. JAMA 1980;244(19):2175-2179.
7. Bergman B, Sörenson S. Smoking and effect of chemotherapy in small cell lung cancer. Eur Respir J 1988;1(10):932-937.
8. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, et al. Continued cigarette smoking by patients receiving concurrent chemo-radiotherapy for limited-stage small cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21(8):1544-1549.
9. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, et al. Smoking cessation before diagnosis and survival in early stage nonsmall cell lung cancer patients. Lung Cancer 2006;53(3):375-380.
10. Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited stage SCLC: a study of 284 patients. Lung Cancer 2010;67(2):221-226.
11. Jerjes W, Upile T, Randi H, Petrie A, Abiola J, Adams A, et al. The effect of tobacco and alcohol and their reduction/cessation on mortality in oral cancer patients: short communication. Head Neck Oncol 2012;4:6.
12. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary nonmuscle-invasive bladder cancer. Eur Urol 2013;63(4): 724-732.
13. Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol 2012;188(6):2120-2127.
14. Braithwaite D, Izano M, Moore DH, Kwan ML, Tammemagi MC, Hiatt RA, et al. Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. Breast Cancer Res Treat 2012;136(2):521-533.
15. Saito-Nakaya K, Nakaya N, Fujimori M, Akizuki N, Yoshikawa E, Kobayakawa M, et al. Marital status, social support and survival after curative resection in non-small-cell lung cancer. Cancer Sci 2006;97(3):206-213.
16. Browman GP, Wong G, Hodson I, Sathya J, Russell R, McAlpine L, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993;328(3):159-163.
17. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small cell lung cancer in the national cancer institute of Canada clinical trials group study BR. Clin Lung Cancer 2006;7(6):389-394.
18. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353(2):123-132.
19. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11(18):6414-6421.
20. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26(19):3128-3137.
21. Kinoshita Y, Tsukuma H, Ajiki W, Kinoshita N, Oshima A, Hiratsuka M, Furukawa H. The risk of second primaries in gastric cancer patients: adjuvant therapy and habitual smoking and drinking. J Epidemiol 2000;10(5):300-304.
22. Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. J Natl Cancer Inst 1997;89(23):1782-1788.
23. Heusch WL, Maneckjee R. Signaling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 1998;19(4):551-556.
24. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7(7):833-839.
25. Huang CH, Powers BC. The evolving role of maintenance therapy using epidermal growth factor receptor tyrosine kinase inhibitors in the management of advanced non-small-cell lung cancer. Clin Med Insights Oncol 2012;6:137-147.
26. Hughes AN, O’Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, et al. Overcoming CYPA1/1A2 mediated induction metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27(8):1220-1226.
27. Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006;12(7 Pt 1):2166-2171.
28. Richardson GE, Tucker MA, Venzon DJ, Linnoila RI, Phelps R, Phares JC, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119(5):383-390.
29. Garces YI, Yang P, Parkinson J, Zhao X, Wampfler JA, Ebbert JO, Sloan JA. The relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 2004;126(6):1733-1741.
30. Gritz ER, Carmack CL, de Moor C, Coscarelli A, Schacherer CW, Meyers EG, Abemayor E. First year after head and neck cancer: quality of life. J Clin Oncol 1999;17(1):352-360.
31. Balduyck B, Sardari Nia P, Cogen A, Dockx Y, Lauwers P, Hendriks J, Van Schil P. The effect of smoking cessation on quality of life after lung cancer surgery. Eur J Cardiothorac Surg 2011;40(6):1432-1437; discussion 1437-1438.
32. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365-376.
33. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30A(5):635-642.
34. Baser S, Shannon VR, Eapen GA, Jimenez CA, Onn A, Lin E, Morice RC. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 2006; 130(6):1784-1790.
35. Ditre JW, Brandon TH. Pain as a motivator of smoking: effects of pain induction on smoking urge and behavior. J Abnorm Psychol 2008;117(2):467-472.
36. Daniel M, Keefe FJ, Lyna P, Peterson B, Garst J, Kelley M, et al. Persistent smoking after the diagnosis of lung cancer is associated with higher reported pain levels. J Pain 2009;10(3):323-328.
37. Ditre JW, Gonzalez BD, Simmons VN, Faul LA, Brandon TH, Jacobsen PB. Associations between pain and current smoking status among cancer patients. Pain 2011;152(1):60-65.
38. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306(7):737-745.
39. Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 2002;90(3):228-239.
40. Browman GP, Mohide EA, Willan A, Hodson I, Wong G, Grimard L, et al. Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. Head Neck 2002; 24(12):1031-1037.
41. Zhang J, Kamdar O, Le W, Rosen GD, Upadhyay D. Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer. Am J Respir Cell Mol Biol 2009;40(2):135-146.
42. Samanta D, Kaufman J, Carbone DP, Datta PK. Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer. Neoplasia 2012;14(7):644-655.
43. Mayer DK, Carlson J. Smoking patterns in cancer survivors. Nicotine Tob Res 2011;13(1):34-40.
44. Nakagawa M, Tanaka H, Tsukuma H, Kishi Y. Relationship between the duration of preoperative smoke-free period and the incidence of postoperative pulmonary complications after pulmonary surgery. Chest 2001;120(3):705-710.